Category: $270M

  • AstraZeneca to Divest Global Rights of Eklira and Duaklir to Covis Pharma in $270M Deal

    Shots: AstraZeneca to receive $270M on completion. The transaction is expected to be close in Q4’21 while Covis will also pay an ongoing development cost related to the therapy The acquisition will strengthen Covis’ respiratory portfolio with the addition of Eklira & Duaklir. Additionally, both therapies are delivered via a Genuair device that is used […]